{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T18:07:58Z","timestamp":1770574078244,"version":"3.49.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis Farma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.clgc.2018.10.001","type":"journal-article","created":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T00:16:46Z","timestamp":1539130606000},"page":"e150-e155","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Safety and Efficacy of Pazopanib in First-Line Metastatic Renal-Cell Carcinoma With or Without Renal Failure: CORE-URO-01 Study"],"prefix":"10.1016","volume":"17","author":[{"given":"Cristina","family":"Masini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Giuseppa","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Maruzzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Procopio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ugo","family":"de Giorgi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0876-0226","authenticated-orcid":false,"given":"Sebastiano","family":"Buti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina","family":"Rossetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1750-2117","authenticated-orcid":false,"given":"Roberto","family":"Iacovelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Atzori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Cosmai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Vignani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Prati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Scagliarini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annalisa","family":"Guida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annalisa","family":"Berselli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmine","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2018.10.001_bib1","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1111\/j.1464-410X.2010.09990.x","article-title":"Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis","volume":"108","author":"Josephs","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2018.10.001_bib2","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/cncr.26201","article-title":"The impact of kidney function on the outcome of metastatic renal cell carcinoma patients treated with vascular endothelial growth factor\u2013targeted therapy","volume":"118","author":"Macfarlane","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2018.10.001_bib3","author":"National Comprehensive Cancer Network"},{"key":"10.1016\/j.clgc.2018.10.001_bib4","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/nrneph.2017.82","article-title":"Targeted therapies for renal cell carcinoma","volume":"13","author":"Posadas","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.clgc.2018.10.001_bib5","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.critrevonc.2016.08.012","article-title":"First-line antiangiogenics for metastatic renal cell carcinoma: a systematic review and network meta-analysis","volume":"107","author":"Rousseau","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clgc.2018.10.001_bib6","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1177\/1756287215614236","article-title":"Pazopanib in the treatment of advanced renal cell carcinoma","volume":"8","author":"Cella","year":"2016","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.clgc.2018.10.001_bib7","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2018.10.001_bib8","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2018.10.001_bib9","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1200\/JCO.2013.50.8267","article-title":"Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study","volume":"32","author":"Escudier","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2018.10.001_bib10","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1517\/14656566.2011.571206","article-title":"Pazopanib for the treatment of renal cancer","volume":"12","author":"Al-Marrawi","year":"2011","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clgc.2018.10.001_bib11","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.ejca.2012.12.010","article-title":"A\u00a0randomised, double-blind phase III study of pazopanib in patients with advanced and\/or metastatic renal cell carcinoma: final overall survival results and safety update","volume":"49","author":"Sternberg","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2018.10.001_bib12","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/annonc\/mdt492","article-title":"Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials","volume":"25","author":"Heng","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2018.10.001_bib13","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1097\/CAD.0b013e328346af0d","article-title":"Safety and efficacy of molecularly targeted agents in patients with metastatic kidney cancer with renal dysfunction","volume":"22","author":"Gupta","year":"2011","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.clgc.2018.10.001_bib14","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1097\/CAD.0000000000000253","article-title":"Baseline chronic kidney disease is associated with toxicity and survival in patients treated with targeted therapies for metastatic renal cell carcinoma","volume":"26","author":"Nouhaud","year":"2015","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.clgc.2018.10.001_bib15","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1093\/annonc\/mdp603","article-title":"Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency","volume":"21","author":"Khan","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2018.10.001_bib16","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.ejca.2013.11.029","article-title":"Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency","volume":"50","author":"Kim","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2018.10.001_bib17","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.ejca.2014.12.010","article-title":"Efficacy of sunitinib in patients with metastatic or unresectable renal cell carcinoma and renal insufficiency","volume":"51","author":"Poprach","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2018.10.001_bib18","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.4143\/crt.2016.018","article-title":"Efficacy and toxicity of mammalian target rapamycin inhibitors in patients with metastatic renal cell carcinoma with renal insufficiency: the Korean Cancer Study Group GU 14-08","volume":"48","author":"Kim","year":"2016","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.clgc.2018.10.001_bib19","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.2174\/1389450117666160112114756","article-title":"Pazopanib in renal cell carcinoma dialysis patients: a mini-review and a case report","volume":"17","author":"Bersanelli","year":"2016","journal-title":"Curr Drug Targets"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876731830096X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876731830096X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:30:58Z","timestamp":1761564658000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155876731830096X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S155876731830096X"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2018.10.001","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and Efficacy of Pazopanib in First-Line Metastatic Renal-Cell Carcinoma With or Without Renal Failure: CORE-URO-01 Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2018.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}